https://www.selleckchem.com/pr....oducts/slf1081851-hy
22; 95% CI, 0.92-5.35; P = 0.08). In addition, lasmiditan seems to result in the increase in dizziness (RR, 6.36; 95% CI, 3.00-13.46; P 0.0001) and paresthesia (RR, 5.10; 95% CI, 2.66-9.78; P 0.00001). Lasmiditan treatment provides additional benefits for pain control in patients with migraine. Lasmiditan treatment provides additional benefits for pain control in patients with migraine. The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the
Like
Comment
Share
